Triastek has the largest product pipeline based on 3D printing technology in the world, with the company’s 1st and 2nd products (T19 and T20) having received IND clearance from the U.S. Food and Drug Administration (FDA). Triastek’s leadership is also demonstrated by acceptance into the U.S. FDA’s Emerging Technology Program (ETP) and participation in the discussion of 3D printing pharmaceutical standards led by United States Pharmacopoeia (USP). The company also holds the highest number of patent applications related to 3D printing of pharmaceuticals, providing the most comprehensive patent coverage of any 3D printing pharmaceutical company in the world.
Having completed 6 rounds of financing, Triastek is well-positioned to advance its product pipeline and positively impact patient health. Investors to date include: Tasly Holding Group, Morningside Venture Capital, Volcanics Venture, Dalton Venture, Yunqi Partners, Matrix Partners China, CPE, Shanghai Sci-Tech Innovation Center Capital, and Triwise Capital.
When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.